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Background: Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. This study
examined whether women with breast cancer prescribed aspirin postdiagnosis had improved survival.
Methods: An observational, population cohort study was undertaken using data linkage of cancer registry, dispensed
prescriptions and death records in Tayside, Scotland. All community prescriptions for aspirin in women with breast cancer were
extracted and use postdiagnosis for each individual examined using Cox’s proportional hazard models. The main outcome
measures were all-cause mortality and breast cancer-specific mortality.
Results: Four thousand six hundred and twenty-seven patients diagnosed with breast cancer between 1 January 1998 and 31
December 2008 were followed up until 28 February 2010. Median age at diagnosis was 62 (IQR 52–74). One thousand eight
hundred and two (39%) deaths were recorded, with 815 (18%) attributed to breast cancer. One thousand and thirty-five (22%)
patients were prescribed aspirin postdiagnosis. Such aspirin use was associated with lower risk of all-cause mortality (HR¼ 0.53,
95% CI¼ 0.45–0.63, Po0.001) and breast cancer-specific mortality (HR¼ 0.42, 95% CI¼ 0.31–0.55, Po0.001) after adjusting for age,
socioeconomic status, TNM stage, tumour grade, oestrogen receptor status, surgery, radiotherapy, chemotherapy, adjuvant
endocrine therapy and aspirin use prediagnosis.
Conclusions: Aspirin use postdiagnosis of breast cancer may reduce both all-cause and breast cancer-specific mortality. Further
investigation seeking a causal relationship and which subgroups of patients benefit most await ongoing randomised controlled trials.
Breast cancer is the most common malignancy in the United
Kingdom, with over 40 000 women diagnosed in 2008 (Maddams
et al, 2009). The molecular events leading to the initiation and
progression of breast cancer are not completely understood;
however, tissue enzymes such as aromatases and prostaglandins
may have a role in the development of the disease.(Kulendran et al,
2009; Hoellen et al, 2011)
Aspirin is a common non-steroidal anti-inflammatory drug
(NSAID) often used for analgesia or at low dosage as an antiplatelet
agent for the prevention of myocardial infarction and stroke.
Aspirin acts by irreversibly inhibiting cyclooxygenase (PTGS,
previously COX-1) and modifies the activity of PTGS-2 required
for the synthesis of prostaglandins. Other NSAIDs, such as ibuprofen,
reversibly inhibit cyclooxygenase. Non-steroidal anti-inflammatory
drugs, particularly aspirin, may have chemopreventive or even
therapeutic properties for several common types of cancer (Gupta
and DuBois, 2001; Rostom et al, 2007; Takkouche et al, 2008).
Several case–control studies have shown a significant
reduction in the risk of breast cancer with NSAID and aspirin
use (Harris et al, 2006; Kirsh et al, 2007). However, prospective
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studies have given mixed results; aspirin has been shown to have
no association (Gill et al, 2007; Jacobs et al, 2007), a decreased risk
(Schreinemachers and Everson, 1994; Harris et al, 2003) or an
increased risk (Friis et al, 2008); non-aspirin NSAIDS have been
associated with a reduced risk (Schreinemachers and Everson,
1994; Harris et al, 2003; Gill et al, 2007).
Aspirin, but not NSAIDs, may interact with other cellular
processes, independent of aromatase and oestrogen expression
(Bardia et al, 2011). An indirect effect of aspirin on mammary
serpin (maspin) has been implicated in the prevention and control
of breast cancer (Zou et al, 1994) and in an animal model by
restoring nitrous oxide synthesis, increasing maspin production
(Bhattacharyya et al, 2010). Overexpression of PTGS-2 in tumours
has also been linked to promoting angiogenesis and inhibiting
apoptosis (Sheng et al, 1998; Rozic et al, 2001), further implicating
that aspirin could prevent growth, metastasis and recurrence.
In the therapeutic setting, a significant reduction in relative risk
by taking aspirin for 2 or more days per week was demonstrated
both for breast cancer metastasis and breast cancer mortality
(Holmes et al, 2010). In a questionnaire-based cohort study of
41 000 postmenopausal women (aged 55–69 years), aspirin was
associated with a reduction in all-cause mortality and breast cancer
mortality (Blair et al, 2007).
The aim of this study was to examine if aspirin use in a
population-based cohort of women with breast cancer postdiagnosis
was associated with all-cause mortality or breast cancer-specific
mortality.
MATERIALS AND METHODS
The Health Informatics Centre (HIC) at the University of Dundee
holds health-related databases on all 400 000 residents of the
Tayside region, Scotland. All women in Tayside diagnosed with
primary invasive breast cancer (ICD10 classifications C50.0–C50.9
or ICD9 classifications 174.0–174.9) between 1 January 1993 and
31 December 2008 and who remained a resident or died in Tayside
were identified and studied from the date of diagnosis to either
death or the study end date (Makubate et al, 2013). Women with a
previous diagnosis of any cancer were excluded. Individual patients
were identified and linked to encashed prescribing, cancer registry and
audit, death certificate and demographic records. Patients were classed
as dying from breast cancer if this was listed on the death certificate as
the underlying cause of death. From the encashed prescribing data
set from 1 January 1993 to 28 February 2010, aspirin prescriptions
were identified and use categorised into: never, prediagnosis only, post
breast cancer diagnosis only or pre- plus postdiagnosis groups.
Aspirin prescribing postdiagnosis included the prescription coverage,
calculated from the number of tablets dispensed and the directions for
use, to determine the number of days the prescription would last if the
patient took the tablets as directed by the prescribing clinician. Thus, a
prescription of 56 tablets with directions of one tablet two times daily
would have a coverage of 28 days.
Patient follow-up postdiagnosis was split into periods of aspirin
use, or non-use, based on aspirin coverage for each individual until
death or the end of follow-up. The total duration of aspirin use was
calculated from the date of the first prescription postdiagnosis to
the end of coverage of the last prescription. Adherence to aspirin
was calculated by dividing the total coverage of the aspirin
prescriptions by the total duration of its use (Makubate et al, 2013).
Ethical approval was granted by the Tayside Committee on
Medical Research Ethics and the NHS Tayside Caldicott Guardian
according to prior arrangements within the HIC (CA/FB HIC
Ethics letter dated 3 February 2010).
Statistical analysis. Data were described as the number of subjects
(percentages) for categorical variables and mean with standard
deviation (s.d.) for continuous variables. Where continuous
variables did not follow a normal distribution, they were tested
using the Shapiro–Wilks test for skewness, and the median and
interquartile range were reported. Likelihood ratios and w2 tests for
trend (w2 trend, degrees of freedom (d.f.), probability (P)) were
reported for differences in distribution of the population with
n-ordered categories, otherwise Pearson’s w2 test for differences
was used (w2, d.f., P).
Cox’s proportional hazards models were utilised to estimate
hazard ratios (HRs) and 95% confidence intervals (CIs) for each
unadjusted and adjusted covariate for cancer diagnosis. Patients were
followed up from cancer diagnosis until the date of death or the end
of the study. Individual patients who used aspirin postdiagnosis had
several linked records each reflecting a period of aspirin use, or no
use, which provided continuous follow-up. This marker of aspirin
use was included in Cox’s proportional hazards model to allow for
the effect over time since diagnosis to be accurately examined. The
proportional hazards assumption was assessed using trend tests of
the Schoenfeld residuals. The multiple regression analysis allowed for
age, socioeconomic status (SES), cancer stage and grade at diagnosis,
ER status, surgery, radiotherapy, chemotherapy, adjuvant endocrine
therapy and aspirin use prediagnosis.
All statistical analyses were performed using Stata version 11
(StataCorp, 2009, Stata Statistical Software: Release 11, College
Station TSL, TX, USA).
RESULTS
There were 4627 women diagnosed with incident breast cancer
over 11 years, 1 January 1998 to 31 December 2008 inclusive (see
Table 1); follow-up was until death or the end of the study period
(28 February 2010). The median age at diagnosis was 62 years (IQR
52–74) and patients were followed up postdiagnosis for 31 444
patient years in total, with a median length of follow-up of 5.7
years (IQR 3.0–10.1). One thousand eight hundred and two
(39.0%) patients died during the study period, with 815 (17.6%)
attributed to breast cancer from death certificate records; 3803
(82%) patients followed up until death or for a minimum of 5 years
postdiagnosis.
There were 682 women (14.7%) who took aspirin before
diagnosis and 1035 (22.4%) took aspirin postdiagnosis of breast
cancer, with a median of 2.4 years use postdiagnosis (IQR 0.7–5.0
years). Calculated adherence to aspirin over the entire period was
high, with a median figure of 95.4% (IQR 81.5–100%). The
majority, 27 484 (99%), of aspirin prescriptions postdiagnosis were
for 75mg dosage. Other characteristics of patients by aspirin use
pre- and postdiagnosis are shown in Table 2. Patients who took
aspirin postdiagnosis were older (w2 trend¼ 400.7, d.f.¼ 5,
Po0.001), had higher SES (w2 trend¼ 50.1, d.f.¼ 5, Po0.001),
lower tumour stage (w2¼ 13.4, d.f.¼ 4, P¼ 0.009), less metastases
(w2¼ 9.8, d.f.¼ 2, P¼ 0.007), lower grade tumours (w2¼ 9.5,
d.f.¼ 3, P¼ 0.023), were less likely to have radiotherapy
(w2¼ 27.0, d.f.¼ 2, Po0.001) or chemotherapy (w2¼ 121.2,
d.f.¼ 2, Po0.001) or surgery (w2¼ 26.5, d.f.¼ 2, Po0.001) and
were more likely to have adjuvant endocrine therapy (w2¼ 74.3,
d.f.¼ 3, Po0.001) (see Table 2).
Using Cox’s regression models, an unadjusted model for all-cause
mortality in patients taking aspirin after diagnosis was created along
with a multiple regression model adjusted for age, SES, tumour
characteristics, surgery, radiotherapy, chemotherapy, adjuvant
endocrine therapy and aspirin use prediagnosis. The adjusted model
showed that aspirin reduced the risk of all-cause mortality
(HR¼ 0.53, 95% CI¼ 0.45–0.63, Po0.001) (Table 3). Increasing
age, tumour stage, lymph node involvement, metastasis and
tumour grade, as well as having chemotherapy were associated
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with an increased risk of all-cause mortality. Increasing social class,
having surgery, positive ER status and using adjuvant endocrine
therapy were associated with a reduced risk of all-cause mortality
(see Supplementary Table 1). However, aspirin use prediagnosis
was associated with increased risk of all-cause mortality
(HR¼ 1.62, 95% CI¼ 1.42–1.85, Po0.001).
Cox’s regression models were also used to report HRs for
patients who died from breast cancer. After adjustment, the use
of aspirin postdiagnosis was associated with a lower risk of breast
cancer mortality (HR¼ 0.42, 95% CI¼ 0.31–0.55, Po0.001).
Increasing tumour stage, lymph node involvement and tumour
grade, the presence of metastases as well as having chemotherapy
were associated with an increased breast cancer mortality.
Having surgery or radiotherapy, positive ER status and using
adjuvant endocrine therapy reduced the risk of breast cancer
mortality. Patients aged 50–59 years were at lower risk than
those aged under 40 years, but there was no other effect by
age and SES had no effect on risk of breast cancer mortality
(see Supplementary Table 2). Again, prediagnosis aspirin use was
associated with an increased risk of breast cancer mortality
(HR¼ 2.10, 95% CI¼ 1.73–2.55, Po0.001).
To examine the effect of adherence to aspirin on all-cause
mortality, patients were classed as having high adherence: 80% or
above (789 patients, 76% of patients taking aspirin postdiagnosis)
or low adherence (246 patients, 24%) and compared with those
patients not taking aspirin. Patients with low adherence had a
reduced HR for death (HR¼ 0.56, 95% CI¼ 0.45–0.69, Po0.001) as
did for those with high adherence (HR¼ 0.55, 95% CI¼ 0.48–0.62,
Po0.001) compared with non-users.
DISCUSSION
Women who used aspirin following a diagnosis of breast cancer
had a reduced risk of all-cause and breast cancer-specific mortality.
Advancing age was related to increased risk of death attributable to
increased comorbidities, such as cardiovascular disease and stroke.
The younger patient age group also fared worse, in keeping with
recognised outcome data (Copson et al, 2013).
Patients in the most affluent socioeconomic quintile had a lower
risk of all-cause mortality as reported elsewhere in the literature
(Fein, 1995; Mackenbach et al, 2003; Marmot, 2003). We found a
significantly higher all-cause mortality risk in those patients who
took aspirin prediagnosis, suggesting aspirin use as a marker of
pre-existing cardiovascular morbidity, which may also mean that
they are unable to receive optimal therapy for breast cancer.
The present population-based cohort study confirms the
reduction in all-cause mortality with aspirin use (adjusted
HR¼ 0.53, 95% CI¼ 0.36–0.79) (Holmes et al, 2010), and breast
cancer-specific mortality (adjusted HR¼ 0.53, 95% CI¼ 0.30–0.93)
(Holmes et al, 2010), or when aspirin was taken postdiagnosis 2–5
days a week (multivariate RR¼ 0.40, 95% CI¼ 0.24–0.65, P¼ 0.03)
(Blair et al, 2007) and 6–7 days a week (multivariate RR¼ 0.57,
95% CI¼ 0.39–0.82, P¼ 0.03) (Blair et al, 2007).







Total number of women 4627 1802 (39.0) 815 (15.0)
Age at diagnosis (years)
o40 207 (4.5) 76 (36.7) 54 (26.1)
40–49 641 (13.9) 156 (24.3) 113 (17.6)
50–59 1100 (23.8) 241 (21.9) 142 (12.9)
60–69 1118 (24.2) 342 (30.6) 151 (13.5)
70–79 883 (19.1) 471 (53.3) 172 (19.5)
80þ 675 (14.6) 515 (76.3) 183 (27.1)
Unknown 3 (0.1) 1 (33.3) 0
Socioeconomic status (SCSIMD5)
1 (most deprived) 599 (12.9) 279 (46.6) 132 (22.0)
2 599 (12.9) 256 (42.7) 115 (19.2)
3 731 (15.8) 299 (40.9) 142 (19.4)
4 1445 (31.2) 577 (39.9) 241 (16.7)
5 (most affluent) 969 (20.9) 339 (35.0) 166 (17.1)
Unknown 284 (6.1) 52 (18.3) 19 (6.7)
Tumour stage
1 1032 (22.3) 277 (26.8) 103 (10.0)
2 1211 (26.2) 553 (45.7) 269 (22.2)
3 259 (5.6) 154 (59.5) 89 (34.4)
4 322 (6.9) 244 (75.8) 152 (47.2)
Unknown 1803 (39.0) 574 (31.8) 202 (11.2)
Node status
N0 2595 (56.1) 887 (34.2) 399 (15.4)
N1 511 (11.0) 318 (62.2) 189 (37.0)
N2 100 (2.2) 78 (78.0) 48 (48.0)
Unknown 1421 (30.7) 519 (36.5) 179 (12.6)
Metastases
No 2959 (64.0) 1122 (37.9) 520 (17.6)
Yes 154 (3.3) 137 (89.0) 89 (57.8)
Unknown 1514 (32.7) 543 (35.9) 206 (13.6)
Tumour grade
G1 469 (10.1) 113 (24.1) 28 (6.0)
G2 1620 (35.0) 498 (30.7) 228 (14.1)
G3 1460 (31.6) 598 (41.0) 346 (23.7)
Unknown 1078 (23.3) 593 (55.0) 213 (19.8)
ER (oestrogen receptor) status
Positive 2766 (59.8) 829 (30.0) 395 (14.3)
Negative 749 (16.2) 361 (48.2) 227 (30.3)
Unknown 1112 (24.0) 612 (55.0) 193 (17.4)
Surgery
No 673 (14.6) 544 (80.8) 280 (41.6)
Yes 3331 (72.0) 918 (27.6) 454 (13.6)
Unknown 623 (13.5) 340 (54.6) 81 (13.0)
Radiotherapy
No 1802 (39.0) 832 (46.2) 356 (19.8)
Yes 2208 (47.7) 636 (28.8) 382 (17.3)
Unknown 617 (13.3) 334 (54.1) 77 (12.5)
Chemotherapy
No 2938 (63.5) 1097 (37.3) 463 (15.8)
Yes 1060 (22.9) 367 (34.6) 272 (25.7)
Unknown 629 (13.6) 338 (53.7) 80 (12.7)
Adjuvant endocrine therapy
None 1364 (29.5) 576 (42.2) 302 (22.1)
Tamoxifen only 2395 (51.8) 953 (39.8) 347 (14.5)
Tamoxifen and AIs 444 (9.6) 154 (34.7) 106 (23.9)
AIs only 424 (9.2) 119 (28.1) 60 (14.2)








Never 3383 (73.1) 1225 (36.2) 563 (16.6)
Prediagnosis only 209 (4.5) 124 (59.3) 68 (32.5)
Pre- and postdiagnosis 473 (10.2) 249 (52.6) 108 (22.8)
Postdiagnosis only 562 (12.2) 204 (36.3) 76 (13.5)
Abbreviation: AIs¼ aromatase inhibitors.
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The study looked at all breast cancers diagnosed from an
unselected population-based cohort, which included people from
all levels of SES and age. The study used dispensed prescribing
records from a closed prescribing system where every prescription
presented to a pharmacist is subsequently recorded and collated.
The prescribing data were then linked to clinical cancer records,
cancer registry records and health board population databases to
provide the study data set.
Limitations include the lack of over-the-counter medication
information for Scotland, although previous work has suggested
that long-term use of aspirin is mainly through prescriptions
(Morant et al, 2004). We did not have recurrence information on
this population as it is not robustly recorded in the routine data
sets this work was based upon. Unfortunately, the indication for
the aspirin prescription and the actual use (rather than filling the
prescription) were not recorded. Most (99%) of the aspirin used
was a low 75mg dose, so it is unlikely to have been used as
analgesia for family members. Similarly, there was no patient data
available on smoking status or BMI, useful in establishing a link to
increased risk of mortality when aspirin was taken prediagnosis.
Long-term low-dose aspirin is associated with an increased risk of
peptic ulcer and gastrointestinal bleeding, but we had no information
on toxicity and side effects from aspirin use (Yeomans, 2011).
It should also be noted that this was an observational study and so
there is the potential for the estimated associations to be the result
of unmeasured residual confounders.
Clinical implications. Our findings demonstrate a substantial
risk reduction in all-cause mortality and breast cancer-specific
mortality when aspirin is taken following a diagnosis of
breast cancer. Because aspirin use was associated with decreased
risk of death from breast cancer, this suggests that aspirin
has a direct interaction with the disease, with PTGS-2 inhibition
a potential molecular mechanism for aspirin to halt the growth
of a tumour and prevent metastasis. It would be very interesting
if the survival benefit gained is due to something as nonspecific
as PTGS-2 inhibition, thus supporting the current prospective
trials of aspirin in breast and other cancer types (Phillips et al,
2013).











Number of women 3592 1035
Age at diagnosis (years)
o40 205 (5.7) 2 (0.2) 400.7, 5, o0.001
40–49 608 (16.9) 33 (3.2)
50–59 934 (26.0) 166 (16.0)
60–69 821 (22.9) 297 (28.7)
70–79 587 (16.4) 296 (28.6)
80þ 434 (12.1) 241 (23.3)
Socioeconomic status (SCSIMD5)
1 (most deprived) 450 (12.5) 149 (14.4) 50.1, 5, o0.001
2 474 (13.2) 125 (12.1)
3 527 (14.7) 204 (19.7)
4 1124 (31.3) 321 (31.0)
5 (most affluent) 759 (21.1) 210 (20.3)
Unknown 258 (7.2) 26 (2.5)
Tumour stage
1 808 (22.5) 224 (21.6) 13.4, 4, 0.009
2 909 (25.3) 302 (29.2)
3 209 (5.8) 50 (4.8)
4 235 (6.5) 87 (8.4)
Unknown 1431 (39.8) 372 (35.9)
Node status
N0 2001 (55.7) 594 (57.4) 1.9, 3, 0.590
N1 392 (10.9) 119 (11.5)
N2 79 (2.2) 21 (2.0)
Unknown 1120 (31.2) 301 (29.1)
Metastases
No 2270 (63.2) 689 (66.6) 9.8, 2, 0.007
Yes 134 (3.7) 20 (1.9)
Unknown 1188 (33.1) 326 (31.5)
Tumour grade
G1 347 (9.7) 122 (11.8) 9.5, 3, 0.023
G2 1235 (34.4) 385 (37.2)
G3 1164 (32.4) 296 (28.6)
Unknown 846 (23.6) 232 (22.4)
ER (oestrogen receptor) status
Positive 2139 (59.6) 627 (60.6) 1.7, 2, 0.428
Negative 595 (16.6) 154 (14.9)
Unknown 858 (23.9) 254 (24.5)
Surgery
No 484 (13.5) 189 (18.3) 26.54, 2, o0.001
Yes 2651 (73.8) 680 (65.7)
Unknown 457 (12.7) 166 (16.0)
Radiotherapy
No 1351 (37.6) 451 (43.6) 27.0, 2, o0.001
Yes 1787 (49.8) 421 (40.7)
Unknown 454 (12.6) 163 (15.8)
Chemotherapy
No 2174 (60.5) 764 (73.8) 121.2, 2, o0.001
Yes 954 (26.6) 106 (10.2)
Unknown 464 (12.9) 165 (15.9)
Adjuvant endocrine therapy
None 1165 (32.4) 199 (19.2) 74.3, 3, o0.001
Tamoxifen only 1806 (50.3) 589 (56.9)
Tamoxifen and AIs 325 (9.1) 119 (11.5)
AIs only 296 (8.2) 128 (12.4)
All-cause mortality 1349 (37.6) 453 (43.8) 13.0, 1, o0.001
Breast cancer mortality 631 (17.6) 184 (17.8) 0.02, 1, 0.875
Abbreviation: AIs¼ aromatase inhibitors.










Ever 2.08 (1.86–2.34), o0.001 1.62 (1.42–1.85), o0.001
Aspirin use
No 1.0 1.0




Ever 2.08 (1.86–2.34), o0.001 1.62 (1.42–1.85), o0.001
Aspirin use
No 1.0 1.0
Yes 1.08 (0.92–1.26), 0.358 0.53 (0.45–0.63), o0.001
The Adjusted Models allowed for age, socio-economic status, cancer stage and grade at
diagnosis, ER status, surgery, radiotherapy, chemotherapy and adjuvant endocrine therapy.
The complete tables are available as supplementary information online.
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Conclusions. This population-based cohort study suggests that
low-dose aspirin prescribed following a diagnosis of breast cancer
is associated with a decreased risk of all-cause and breast cancer-
specific mortality. Further studies are needed to investigate the
exact mechanism of this protective effect. Prospective randomised
clinical trials may well define the effectiveness of aspirin for specific
patient subgroups in the near future.
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